Response to Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL + human leukemia"

LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.

Saved in:
Bibliographic Details
Published in:Science translational medicine 2019-07, Vol.11 (501)
Main Authors: Lai, Damian, Chen, Min, Su, Jiechuang, Liu, Xiaohu, Rothe, Katharina, Hu, Kaiji, Forrest, Donna L, Eaves, Connie J, Morin, Gregg B, Jiang, Xiaoyan
Format: Article
Language:English
Subjects:
BCR-ABL protein
Bone marrow
Drug Resistance, Neoplasm - drug effects
Fusion protein
Fusion Proteins, bcr-abl
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplastic Stem Cells - drug effects
Progenitor cells
Protein Kinase Inhibitors
Stem cells
Tyrosine kinase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:LB100 sensitizes resistant chronic phase CML stem and progenitor cells to TKIs and spares healthy bone marrow cells.
ISSN:1946-6234
1946-6242
1946-3242
DOI:10.1126/scitranslmed.aav0819